NNOX — Nano-X Imaging Ltd.

Nano-X Imaging Ltd. Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• GAAP Net Loss: $13.7 million, slightly up from $13.6 million in Q3 2024.
• Revenue: $3.4 million, compared to $3 million in the same period last year.
• Gross Loss: $2.9 million on a GAAP basis, with a non-GAAP gross loss of $300,000 (8% margin).
• Teleradiology Revenue: $3.1 million, with a gross profit of $100,000 (25% margin).
• AI Solutions Revenue: $100,000, down from $400,000 in Q3 2024, with a gross loss of $1.9 million.
• Cash Position: $55.5 million in cash, cash equivalents, and marketable securities.

2. Strategic Updates and Business Highlights:

• Global Expansion: Signed agreements in the Czech Republic and France, enhancing European presence.
• Technology Development: Preparing to launch the next-generation Nano-X ArcX system at the RSNA annual meeting.
• AI Integration: Announced acquisition of Vaso Healthcare IT for $800,000 to enhance AI capabilities and customer service.
• Clinical Collaborations: Engaged with Cedars-Sinai and MDS Wellness for clinical trials to validate the Nano-X ARC's effectiveness in lung cancer detection.
• Operational Efficiency: Strengthening production capabilities through partnerships with Fabrinet and Varex.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance: Projecting over $35 million, driven by expanding deployments and new partnerships.
• AI Business Breakeven: Expected quarterly breakeven in 2026, with overall company breakeven anticipated in 2027.
• Sales Growth: Anticipated gradual revenue ramp-up, particularly in the latter half of 2026.

4. Bad News, Challenges, or Points of Concern:

• Regulatory Delays: Ongoing challenges with FDA approvals, particularly regarding the removal of adjunctive use limitations.
• Declining AI Revenue: Notable decrease in revenue from AI solutions, raising concerns about market traction.
• Operational Costs: Increased operating expenses, particularly in sales and marketing, which may pressure profitability in the short term.

5. Notable Q&A Insights:

• System Deployment: Management confirmed a few dozen systems are actively scanning, with plans for more installations.
• Revenue Composition: Revenue for the quarter derived from a mix of scans and OEM services, with expectations for continued growth in capital expenditures.
• Teleradiology Growth: While teleradiology services showed strong growth, future revenue projections are conservative, focusing on existing business rather than significant leaps.
• Vaso Acquisition Impact: The acquisition is expected to enhance cross-selling opportunities and expand the customer base significantly.

Overall, Nano-X Imaging Ltd. is positioned for growth with strategic partnerships and technology advancements, despite facing regulatory hurdles and declining metrics in certain areas. The company remains focused on achieving profitability through its comprehensive imaging platform and AI integration.